|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
AVAX Technologies Inc., of Overland Park, Kan., reported publication in the August 2002 issue of Cancer Immunology, Immunotherapy studies related to its AC Vaccine cancer technology. The paper was a retrospective analysis of dosing regimens given to 284 melanoma patients meant to determine the impact of live and dead cells in eliciting an immune response, as measured by delayed-type hypersensitivity testing, to their own tumor cells. The paper concluded that dead tumor cells appear to contribute to the vaccine's immunogenicity.
Bioenvision Inc., of New York, published data in Cancer Cell Biology on the mode of action of Modrenal. The data showed that the drug ...